Pulse Biosciences, Inc.
PLSE
$17.19
$0.704.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 74.51% | 51.62% | 32.40% | 7.40% | -19.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.71% | 29.11% | 22.00% | -0.91% | -11.81% |
| Operating Income | -42.71% | -29.11% | -21.98% | 0.93% | 11.36% |
| Income Before Tax | -41.59% | -26.95% | -16.87% | 6.24% | 16.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.59% | -26.95% | -16.87% | 6.24% | 16.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.59% | -26.95% | -16.87% | 6.24% | 16.63% |
| EBIT | -42.71% | -29.11% | -21.98% | 0.93% | 11.36% |
| EBITDA | -43.99% | -30.00% | -22.80% | 0.78% | 11.41% |
| EPS Basic | -21.92% | -1.93% | 11.98% | 35.59% | 44.75% |
| Normalized Basic EPS | -21.92% | -1.91% | 11.49% | 35.33% | 44.56% |
| EPS Diluted | -21.92% | -1.93% | 11.98% | 35.59% | 44.75% |
| Normalized Diluted EPS | -21.92% | -1.91% | 11.49% | 35.33% | 44.56% |
| Average Basic Shares Outstanding | 15.01% | 21.51% | 29.77% | 43.31% | 50.16% |
| Average Diluted Shares Outstanding | 15.01% | 21.51% | 29.77% | 43.31% | 50.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |